卡介苗菌株治疗非肌层浸润性膀胱癌疗效的系统综述与网络Meta分析
该系统综述与网络Meta分析纳入65项试验、12246例患者、9种卡介苗菌株,比较卡介苗菌株与化疗及非卡介苗生物疗法对非肌层浸润性膀胱癌复发的预防效果。以膀胱内化疗为共同对照时,Tokyo-172、Pasteur和TICE菌株预防复发显著优于化疗,但各菌株之间无显著优劣差异。
要点
- 以化疗为共同对照,Tokyo-172(OR 0.39,95%CI 0.16-0.93)、Pasteur(OR 0.49,95%CI 0.28-0.86)和TICE(OR 0.61,95%CI 0.40-0.93)菌株预防复发显著优于化疗。
- 网络Meta分析中,各卡介苗菌株之间预防复发无显著优劣差异。
- 作者认为尚无法就菌株优劣得出明确结论,亟需头对头试验进一步了解菌株选择对卡介苗疗效的重要性。
核心结论
- 卡介苗菌株与化疗相比在疗效上存在显著差异。
- 关于菌株优劣尚无法得出明确结论,亟需头对头试验进一步了解菌株选择对卡介苗疗效的重要性。
研究设计与样本
- 系统综述与网络Meta分析,评估卡介苗菌株与所有可能对照(不同卡介苗菌株、化疗、非卡介苗生物疗法)的试验,以膀胱内化疗为共同对照。
- MEDLINE®为主要数据源,检索自建库至2016年10月,纳入接受卡介苗的非肌层浸润性膀胱癌患者的临床试验。
- 主要结局为膀胱癌复发,定义为任何分级或分期的复发性膀胱肿瘤。
- 采用随机效应网络Meta分析,结果以比值比(OR)表示。
- 全部对照比较共纳入65项试验、12246例患者、9种菌株。
主要发现
- 全部对照比较中,治疗患者5642例中复发2177例(38.6%),对照5441例中复发2316例(42.6%)。
- 以化疗为共同对照的比较共28项试验、5757例患者、5种菌株。
- Tokyo-172菌株较化疗显著降低复发(OR 0.39,95%CI 0.16-0.93)。
- Pasteur菌株较化疗显著降低复发(OR 0.49,95%CI 0.28-0.86)。
- TICE®菌株较化疗显著降低复发(OR 0.61,95%CI 0.40-0.93);网络Meta分析中各卡介苗菌株之间预防复发无显著优劣差异。
关键数值与推荐
- 复发定义:任何分级或分期的复发性膀胱肿瘤。
- 以化疗为共同对照,Tokyo-172(OR 0.39,95%CI 0.16-0.93)、Pasteur(OR 0.49,95%CI 0.28-0.86)和TICE®(OR 0.61,95%CI 0.40-0.93)菌株预防复发显著优于化疗。
- 网络Meta分析中,任何卡介苗菌株相较其他菌株在预防复发方面均未显示显著优势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为关于菌株优劣尚无法得出明确结论。
- 作者认为亟需头对头试验进一步了解菌株选择对卡介苗疗效的重要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to determine the efficacy of genetically distinct bacillus Calmette-Guérin strains in preventing disease recurrence in patients with nonmuscle invasive bladder cancer. MATERIALS AND METHODS: We conducted a systematic review and network meta-analysis of trials evaluating bacillus Calmette-Guérin strains against all possible comparators (different bacillus Calmette-Guérin strains, chemotherapy and nonbacillus Calmette-Guérin biological therapies) with intravesical chemotherapy as the common comparator. MEDLINE® (http://www.ncbi.nlm.nih.gov/pubmed) served as the primary data source, with the search from inception to October 2016 for clinical trials involving patients with nonmuscle invasive bladder cancer receiving bacillus Calmette-Guérin. Primary outcome measure was bladder cancer recurrence, defined as recurrent bladder tumor of any grade or stage. Random effect network meta-analysis provided estimates for outcomes and is presented as odds ratios. RESULTS: Across all possible comparators (65 trials, 12,246 patients, 9 strains) there were 2,177 recurrences in 5,642 treated patients (38.6%) and 2,316 recurrences in 5,441 comparators (42.6%). With chemotherapy as the common comparator (28 trials, 5,757 patients, 5 strains) Tokyo-172 (OR 0.39, 95% CI 0.16-0.93), Pasteur (OR 0.49, 95% CI 0.28-0.86) and TICE® (OR 0.61, 95% CI 0.40-0.93) strains were significantly better than chemotherapy at preventing recurrence. No bacillus Calmette-Guérin strain demonstrated significant superiority when compared to any other strain at preventing recurrence in the network meta-analysis. CONCLUSIONS: Bacillus Calmette-Guérin strains exhibited significant differences in efficacy compared to chemotherapy. However, no definitive conclusions could be reached regarding strain superiority, and head-to-head trials are greatly needed to further understand the importance of strain selection in determining bacillus Calmette-Guérin efficacy.
引用
- Boehm BE, Cornell JE, Wang H, et al. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis. J Urol. 2017. PMID: 28286068. doi:10.1016/j.juro.2017.01.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。